• 800-459-1185
  • Email us
Client Portal Login
CSI-Laboratories
  • Home
  • Services
    • Flow Cytometry

      Advanced 10-color flow cytometry and rapid turnaround times.

    • FISH

      Identifying genetic abnormalities on disease-specific genes locations.

    • Histology

      A complete menu of immunohistochemistry, special stains, and In Situ Hybridization (ISH) assays.

    • Cytogenetics

      Analyzing the entire chromosome set for numerical and structural abnormalities.

    • Molecular

      PCR, NGS and Sanger qualitative and quantitative analysis of hematopoetic and solid tumors.

    • Tech-Only

      Client pathologists perform the professional interpretation of test results.

    • Consultation

      Speak with our caring team of expert pathologists.

  • About Us
    • about-us

      About CSI

      We are a privately-owned national cancer testing laboratory with one mission: Keeping our clients and their patients at the forefront of everything we do. Our priority is to manage testing with speed, precision and care, only delivering testing that is medically necessary and clinically significant.

      • Leadership Team
      • Medical Team
      • Press Room
      • History
      • Careers
  • Resources
  • CSI Institute
    • csi

      About CSI

      As a leading cancer reference laboratory, our mission is to provide the best in-person and online resources for physicians and laboratory professionals. CSI Institute provides insights into best practices, cancer research, and technology to support our clients and their patients.

      • White Papers
      • Webinar
  • Contact Us
  • Client Portal Login
    • Email us

Press Room

CSI in the News

11/13/2019 – 08:00 AM
CSI Laboratories Announces Expanded Tech-Only FISH Menu

08/21/2019 – 08:00 AM
CSI Laboratories Announces New Line of Capital

07/09/2019 – 07:30 AM
CSI Laboratories Announces Equity Stake Acquisition by Synergy Capital Investments

03/18/2019 – 07:30 AM
CSI Laboratories Begins Offering VENTANA PD-L1 (SP142) Assay as Companion Diagnostic Test for Triple Negative Breast Cancer as a Result of FDA Approval for TENCENTRIQ® (atezolizumab)

02/12/2019 – 08:30 AM
CSI Laboratories Announces Opening of New Laboratory in Jupiter, Fla.

12/05/2018 – 10:30 AM
CSI Laboratories Advances Precision in Cancer Diagnostics by Partnering with Dr. Maher Albitar of Genomics Testing Cooperative (GTC)

02/20/2018 – 05:00 AM
CSI Laboratories Announces Construction of New Cancer Diagnostics Laboratory in Florida

03/14/2017 – 09:00 AM
CSI Laboratories Partnership with Avalon Healthcare Solutions to Benefit Patients in South Carolina

07/08/2016 – 09:56 PM
CSI Laboratories Now Offering PD-L1 Expression Assay Used in Conjunction with Multiple Immunotherapies

05/28/2015 – 04:45 AM
CSI Laboratories Holds Ribbon Cutting Ceremony for New Molecular Laboratory

12/01/2014 – 04:09 PM
CSI Laboratories Breaks Ground on Multimillion-Dollar Molecular Laboratory

  • CAP-Accredited
  • CLIA-Accredited
  • COG-Accredited
CSI-Laboratories
  • CAP Accreditation Number: 6865201
  • CLIA Certification Number: 11D0933321
  • COG Childrens Oncology Group
  • About CSI
  • Our Team
  • Client Resources
  • CSI Institute
  • Press Room
  • Careers
  • Client Portal
  • Contact
  • Client Portal Login
  • 800-459-1185
© Copyright 2019 CSI Laboratories. All Rights Reserved.
  • Privacy & Security
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.